Statins for Lowering Cholesterol Cause Muscle Weakness; CBCD Suggests Taking Muxscle against the Muscle Weakness Side Effect

Share Article

The Center for the Biology of Chronic Disease (CBCD) suggests that patients who take statins to lower their cholesterol levels also consider taking Muxscle against the muscle weakness side effect of statins.

A recent study published in the Canadian Medical Association Journal showed that a common side effect of patients who take statins is persistent myopathy, which means that their muscle fibers do not function properly, resulting in muscle weakness. In addition, a recent review of the side effect of statins published in Pharmacological Reports writes that "Clinical trials commonly define statin toxicity as myalgia or muscle weakness." Surprisingly, the review also writes that "The exact pathophysiology of statin-induced myopathy is not fully known," and that "Currently, the only effective treatment of statin-induced myopathy is the discontinuation of statin use." Finally, another review published in the European Journal of Internal Medicine says that "myotoxicity induced by statins is a common adverse event and a major barrier to maximizing cardiovascular risk reduction."

Statins are a class of drugs used by patients to lower their cholesterol levels. The best-selling statin is Lipitor, manufactured by Pfizer. In 2003, Lipitor became the best-selling pharmaceutical in history. Currently, there are many statins on the market, including atorvastatin (Lipitor and Torvast), fluvastatin (Lescol), lovastatin (Mevacor, Altocor, Altoprev), pitavastatin (Livalo, Pitava), pravastatin (Pravachol, Selektine, Lipostat), rosuvastatin (Crestor) and simvastatin (Zocor, Lipex).

The CBCD suggests that patients taking one of these statins, and are at risk of developing muscle weakness as a side effect, consider also taking Muxscle. Muxscle is a dietary supplement that increases physical strength by stimulating the signal that nerves send to muscles. Muxscle has been clinically tested by scientists at the Center for the Biology of Chronic Disease (CBCD). The scientists found that it safely increased the overall physical strength of the participants in the study. They also found that it improved those daily activities that required the use of physical strength. The study is currently awaiting publication in scientific journals.

An abstract of the scientific study is available on the CBCD website at A scientific explanation of the Muxscle effect on the neuromuscular junction is also available on the CBCD website at

Those who have a hard time fully understanding the science and terminologies in the CBCD reports should show them to their doctor. A print-ready copy of the abstract is available at

A website that includes information about Muxscle written for the general public is available at


Mohaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer L, Hoppeler H, Breil F, Draeger A. Association between statin-associated myopathy and skeletal muscle damage. CMAJ. 2009 Jul 7;181(1-2):E11-8.

Tomaszewski M, Stępień KM, Tomaszewska J, Czuczwar SJ. Statin-induced myopathies. Pharmacol Rep. 2011;63(4):859-66.

Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012 Jun;23(4):317-24. Epub 2012 Feb 4.

John S. Boyd, Ph.D.

The Center for the Biology of Chronic Disease (CBCD, is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments.

The CBCD published the “Purple” book by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between foreign DNA and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John Boyd
Center for the Biology of Chronic Disease (CBCD).
(585) 250-9999
Email >
Visit website